We are live on ! Find out more
SLNOW

Soleno Therapeutics, Inc. Series A Warrant

Delisted

SLNOW was delisted on the 8th of November, 2019.

2 hedge funds and large institutions have $29K invested in Soleno Therapeutics, Inc. Series A Warrant in 2019 Q1 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% less funds holding

Funds holding: 32 (-1)

86% less capital invested

Capital invested by funds: $205K → $29K (-$176K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
2
Holders Change
-1
Holders Change %
-33.33%
% of All Funds
0.04%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
1
Closed
1
Calls
Puts
Net Calls
Net Calls Change

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
6CM
683 Capital Management
New York
-$186K
2
UBS Group
UBS Group
Switzerland
-$886
Name Holding Trade Value Shares
Change
Change in
Stake
VC
1
Vivo Capital
California
$28K
UBS Group
2
UBS Group
Switzerland
$1K -$886 -5,250 -49%
6CM
3
683 Capital Management
New York
-$186K -602,443 Closed

SLNOW Hedge Fund Activity: Q1 2019 in Review

2 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics, Inc. Series A Warrant (SLNOW) for Q1 2019, worth a combined $29K — down 86% from $205K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of SLNOW and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.

The largest seller was 683 Capital Management, exiting entirely with an estimated $186K sold.

  • 2 institutional investors held Soleno Therapeutics, Inc. Series A Warrant (SLNOW) as of Q1 2019, down from 3 in Q4 2018.
  • Funds reported $29K of Soleno Therapeutics, Inc. Series A Warrant stock for Q1 2019, down 86% quarter-over-quarter.
  • 0 funds opened new Soleno Therapeutics, Inc. Series A Warrant positions in Q1 2019 and 1 closed out, a net change of -1 holder.
  • The largest Soleno Therapeutics, Inc. Series A Warrant seller in Q1 2019 was 683 Capital Management, an estimated $186K sold.

Based on aggregated 13F filings for Q1 2019.